Skip to content
Review Open access

The Role of Curcumin in Neurogenesis and Neuroprotection in Alzheimer’s disease: From Molecular Mechanisms to Clinical Evidence

Sep 2026 · International Journal Of Recent Trends In Multidisciplinary Research · 0 citations

TL;DR

This review discusses multi-target neuroprotective mechanisms of curcumin, critically reviews the preclinical success and human clinical trial outcomes, and highlights advanced nano formulations (solid lipid nanoparticles, colloidal sub-micron dispersions, polymeric nanoparticles, multi-walled carbon nanotubes and exosomes) and synergistic combination regimens to maximise its CNS bioavailability and therapeutic efficacy in humans.

Abstract

Alzheimer's disease (AD) is the most common form of senile dementia worldwide and is a progressive and irreversible neurodegenerative disorder, which represents a huge socioeconomic burden on modern healthcare systems. The neuropathology of AD is characterised by a very complex, interconnected cascade of cellular events including the extracellular accumulation of neurotoxic amyloid-beta (Aβ) peptides in senile plaques, the intracellular aggregation of hyperphosphorylated tau protein in neurofibrillary tangles (NFTs), chronic neuroinflammation, severe oxidative damage, cholinergic deficits and synaptic collapse. Standard FDA approved therapies provide modest symptomatic relief, leading to intensive research into multi-target disease modifying natural compounds. Curcumin is a natural hydrophobic diarylheptanoid polyphenol isolated from the rhizome of the turmeric plant (Curcuma longa) and has been proposed as a promising multi-target therapeutic candidate due to its strong antioxidant, anti-inflammatory, anti-protein-aggregating and neurogenic activities. Preclinical studies have demonstrated that curcumin can modulate a variety of pathological pathways. Curcumin down-regulates BACE1 expression and alters APP processing; it binds directly to Aβ monomers and fibrils to inhibit their aggregation and to promote the disaggregation of plaques. Curcumin blocks kinases (such as GSK- 3β) to prevent tau hyperphosphorylation, increases Nrf2-mediated antioxidant enzyme expression, chelates transition metals, inhibits NF-κB-dependent chronic inflammatory cascades, and promotes adult hippocampal neurogenesis. However, the clinical translation of curcumin is severely hampered by the “bioavailability barrier” that is manifested by poor aqueous solubility, extensive first-pass metabolism in the intestine and liver, rapid systemic clearance and limited penetration across the blood-brain barrier (BBB). This review discusses multi-target neuroprotective mechanisms of curcumin, critically reviews the preclinical success and human clinical trial outcomes, and highlights advanced nano formulations (solid lipid nanoparticles, colloidal sub-micron dispersions, polymeric nanoparticles, multi-walled carbon nanotubes and exosomes) and synergistic combination regimens to maximise its CNS bioavailability and therapeutic efficacy in humans.

Read PDF

Similar papers

Review Open access Oct 2026

Recent advances of GPR40 agonists as potential anti-Alzheimer's agents.

Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disorder involving metabolic dysfunction, neuroinflammation, mitochondrial impairment, synaptic failure, and neuronal loss. Although amyloid-beta deposition and neurofibrillary tangles composed of hyperphosphorylated tau remain central patho...

Jefferson Muniz Alves da Silva, A. Kümmerle, D. A. Rodrigues et al. · 0 citations
Review Open access Sep 2026

The Role of Neuroinflammation in Alzheimer's Disease: Molecular Mechanisms and Emerging Therapeutic Approaches

This review examines the molecular and cellular mechanisms through which neuroinflammation contributes to the progression of AD, with particular emphasis on microglial activation, TREM2 and soluble TREM2 (sTREM2) signaling, NLRP3 inflammasome activation, astrocyte–microglia interactions, and blood–brain barrier dysfunc...

Shreyansh Goswami · 0 citations
Review Aug 2026

Neuropharmacological Interventions in Alzheimer’s Disease: Current and Emerging Approaches

Current preclinical and emerging evidence indicate that the modulation of interconnected pathological pathways, including mitochondrial dysfunction, insulin resistance, and neuroinflammation, may lead to improved therapeutic outcomes, and the incorporation of early diagnostic biomarkers in conjunction with the use of m...

Lalit Parihar, A. Singh, Sanjar Alam · 0 citations
Review Open access Sep 2026

Natural compounds targeting glial activation in Alzheimer’s disease: a review of curcumin, resveratrol, and luteolin

Preclinical evidence suggests that these natural substances show potential as therapeutic candidates for Alzheimer’s disease, although further clinical studies are still needed to confirm their efficacy and safety.

N. Yuniarti, Rani Resdiani, M. D. Laksitorini et al. · 0 citations
Review Sep 2026

Alzheimer's Disease (AD) Neuroinflammation and Excitotoxicity: Mechanisms and New Treatment Approaches

Key results show that using anti-inflammatory drugs and therapies that support calcium balance can effectively interrupt the pathological cycle between neuroinflammation and excitotoxicity, and Simultaneously targeting multiple interconnected pathogenic pathways is a promising therapeutic strategy for reducing neurodeg...

Mayank Saini, Tanuj Hooda, A. Sood et al. · 0 citations
Review Sep 2026

Immunity and Inflammation in Alzheimer's Disease: A Narrative Review on Mechanisms and Therapeutic Prospects.

This review systematically summarizes the core pathophysiological mechanisms by which inflammatory and immune dysfunctions contribute to AD pathogenesis and explores potential therapeutic interventions targeting these mechanisms, thereby providing theoretical insights for clinical translational research on AD treatment...

Lu-Ping Chi, Feng-Qing Xu, Xiao-Ying Dai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.